These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 20050905)
1. Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate. Kieseier BC; Hartung HP Eur J Neurol; 2010 Mar; 17(3):344-5. PubMed ID: 20050905 [No Abstract] [Full Text] [Related]
2. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study. Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? Bever CT; Rosenberg GA Neurology; 1999 Oct; 53(7):1380-1. PubMed ID: 10534237 [No Abstract] [Full Text] [Related]
5. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis. Yılmaz Ü; Gücüyener K; Atak A; Aral A; Gürkaş E; Demir E; Serdaroğlu A Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Hegen H; Auer M; Deisenhammer F Expert Opin Drug Metab Toxicol; 2015; 11(12):1803-19. PubMed ID: 26419922 [TBL] [Abstract][Full Text] [Related]
14. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J; Lublin FD Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]
15. Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. Bermel RA; Cohen JA Lancet Neurol; 2011 Jan; 10(1):4-5. PubMed ID: 21163434 [No Abstract] [Full Text] [Related]
16. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis. Duddy M; Palace J Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247 [No Abstract] [Full Text] [Related]
17. [Neuroprotective effect of the long-term beta-interferon course in multiple sclerosis: direct and indirect mechanisms]. Gusev EI; Boĭko AN; Khachanova NV; Demina TL; Davydovskaia MV Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):70-3. PubMed ID: 16841488 [No Abstract] [Full Text] [Related]
18. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Polman CH; Bertolotto A; Deisenhammer F; Giovannoni G; Hartung HP; Hemmer B; Killestein J; McFarland HF; Oger J; Pachner AR; Petkau J; Reder AT; Reingold SC; Schellekens H; Sørensen PS Lancet Neurol; 2010 Jul; 9(7):740-50. PubMed ID: 20610349 [TBL] [Abstract][Full Text] [Related]
19. Neutralising antibodies against interferon beta in multiple sclerosis. Mikol D Lancet; 2004 Jan; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179 [No Abstract] [Full Text] [Related]
20. Combining two multiple sclerosis treatments has no clinical benefit, study finds. Anekwe L BMJ; 2013 Mar; 346():f1719. PubMed ID: 23491460 [No Abstract] [Full Text] [Related] [Next] [New Search]